Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer.

Valdés-Mora F, Gould CM, Colino-Sanguino Y, Qu W, Song JZ, Taylor KM, Buske FA, Statham AL, Nair SS, Armstrong NJ, Kench JG, Lee KML, Horvath LG, Qiu M, Ilinykh A, Yeo-Teh NS, Gallego-Ortega D, Stirzaker C, Clark SJ.

Nat Commun. 2017 Nov 7;8(1):1346. doi: 10.1038/s41467-017-01393-8.

2.

Screening of potential therapy targets for prostate cancer using integrated analysis of two gene expression profiles.

Zhao R, Wang Y, Zhang M, Gu X, Wang W, Tan J, Wei X, Jin N.

Oncol Lett. 2017 Nov;14(5):5361-5369. doi: 10.3892/ol.2017.6879. Epub 2017 Sep 4.

3.

Clinical relevance of androgen receptor alterations in prostate cancer.

Jernberg E, Bergh A, Wikström P.

Endocr Connect. 2017 Nov;6(8):R146-R161. doi: 10.1530/EC-17-0118. Review.

4.

lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.

Gu P, Chen X, Xie R, Han J, Xie W, Wang B, Dong W, Chen C, Yang M, Jiang J, Chen Z, Huang J, Lin T.

Mol Ther. 2017 Aug 2;25(8):1959-1973. doi: 10.1016/j.ymthe.2017.04.016. Epub 2017 May 6.

PMID:
28487115
5.

Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer.

Obinata D, Takayama K, Takahashi S, Inoue S.

Cancers (Basel). 2017 Feb 28;9(3). pii: E22. doi: 10.3390/cancers9030022. Review.

6.

An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.

Chen Q, Weng Z, Lu Y, Jia Y, Ding L, Bai F, Ge M, Lin Q, Wu K.

PLoS One. 2017 Jan 3;12(1):e0168960. doi: 10.1371/journal.pone.0168960. eCollection 2017.

7.

The role of GATA2 in lethal prostate cancer aggressiveness.

Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J.

Nat Rev Urol. 2017 Jan;14(1):38-48. doi: 10.1038/nrurol.2016.225. Epub 2016 Nov 22. Review.

8.

Emerging data on androgen receptor splice variants in prostate cancer.

Cao S, Zhan Y, Dong Y.

Endocr Relat Cancer. 2016 Dec;23(12):T199-T210. Epub 2016 Oct 4. Review.

9.
10.

BAP18 coactivates androgen receptor action and promotes prostate cancer progression.

Sun S, Zhong X, Wang C, Sun H, Wang S, Zhou T, Zou R, Lin L, Sun N, Sun G, Wu Y, Wang B, Song X, Cao L, Zhao Y.

Nucleic Acids Res. 2016 Sep 30;44(17):8112-28. doi: 10.1093/nar/gkw472. Epub 2016 May 25.

11.

Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.

Sunkel B, Wu D, Chen Z, Wang CM, Liu X, Ye Z, Horning AM, Liu J, Mahalingam D, Lopez-Nicora H, Lin CL, Goodfellow PJ, Clinton SK, Jin VX, Chen CL, Huang TH, Wang Q.

Nucleic Acids Res. 2016 May 19;44(9):4105-22. doi: 10.1093/nar/gkv1528. Epub 2016 Jan 6.

12.

Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer.

Chen Z, Lan X, Wu D, Sunkel B, Ye Z, Huang J, Liu Z, Clinton SK, Jin VX, Wang Q.

Nat Commun. 2015 Sep 16;6:8323. doi: 10.1038/ncomms9323.

13.

Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.

Alshalalfa M, Schliekelman M, Shin H, Erho N, Davicioni E.

Biol Cell. 2015 Jul;107(7):232-44. doi: 10.1111/boc.201400097. Epub 2015 Jun 16.

14.

Androgen receptor epigenetics.

Cai C, Yuan X, Balk SP.

Transl Androl Urol. 2013 Sep 1;2(3):148-157.

15.

Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.

Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, Wang L, Sunkel B, Grenade C, Chen J, Zynger DL, Yan PS, Huang J, Nephew KP, Huang TH, Lin S, Clinton SK, Li W, Jin VX, Wang Q.

EMBO J. 2015 Feb 12;34(4):502-16. doi: 10.15252/embj.201490306. Epub 2014 Dec 22.

16.

MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand.

Liu G, Sprenger C, Wu PJ, Sun S, Uo T, Haugk K, Epilepsia KS, Plymate S.

Oncotarget. 2015 Jan 1;6(1):288-304.

17.

MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples.

Cannistraci A, Di Pace AL, De Maria R, Bonci D.

Biomed Res Int. 2014;2014:146170. doi: 10.1155/2014/146170. Epub 2014 Sep 16. Review.

18.

Molecular pathways and targets in prostate cancer.

Shtivelman E, Beer TM, Evans CP.

Oncotarget. 2014 Sep 15;5(17):7217-59. Review.

19.

Influence of oncogenic transcription factors on chromatin conformation and implications in prostate cancer.

Yang YA, Kim J, Yu J.

Appl Clin Genet. 2014 May 12;7:81-91. doi: 10.2147/TACG.S35598. eCollection 2014. Review.

20.

Med1 subunit of the mediator complex in nuclear receptor-regulated energy metabolism, liver regeneration, and hepatocarcinogenesis.

Jia Y, Viswakarma N, Reddy JK.

Gene Expr. 2014;16(2):63-75. doi: 10.3727/105221614X13919976902219. Review.

Supplemental Content

Support Center